Biotech selling Arcalyst, an interleukin blocker for recurrent pericarditis, a rare heart-lining inflammation.
Biotech selling Arcalyst, an interleukin blocker for recurrent pericarditis, a rare heart-lining inflammation.
Sells Arcalyst as a weekly injection, taken by patients for years through specialty pharmacies, so revenue grows as more people are diagnosed and stay on treatment. It licenses Arcalyst from Regeneron, which makes the drug and receives payments in return, so a share of each sale goes back to its originator.
Moat: narrow (IP / patents, regulatory licence). First and only approved therapy specifically for recurrent pericarditis, with orphan-drug protection.
Headquarters: Lexington, Massachusetts, United States · Founded: 2015 · Employees: 366
Size Kiniksa Pharmaceuticals International (KNSA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.47B, the 918th largest of 3,085 United States companies the cockpit tracks. Shares closed at $95.05 on 18 Nov 2026.
Performance Over six months the shares gained 75.1%, against +2.7% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 58.2% over the last twelve months (peer median +11.5%); the operating margin is 13.8% (peer median 15.1%).
Valuation It trades at 56.6× forward earnings against a peer median of 16.4× (2nd most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +45%, so the hurdle is -35 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 62.5 points above its cost of capital (6.6% WACC).
Short interest Short interest is 8.8% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $946M | $678M | $423M | $270M | $220M |
| Revenue growth | — | +60% | +57% | +23% | — |
| Gross profit | $513M | $370M | $234M | $179M | $169M |
| EBITDA | $132M | $78.8M | -$43.9M | -$23.1M | $14.0M |
| Net income | $110M | $59.0M | -$43.2M | $14.1M | $183M |
| Free cash flow | $197M | $136M | $25.4M | $13.2M | $5.70M |
| Capital expenditure | $1.64M | $1.57M | $277,000 | $130,000 | $105,000 |
| Total debt | $7.88M | $9.50M | $9.86M | $12.3M | $5.92M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International KNSA | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 17.5× | 1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KNSA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.3% | +1.7% | 3rd highest of 21 |
| 6-month return | +75.1% | +2.7% | 2nd highest of 21 |
| Distance from 52-week high | -4.3% | -12.9% | 5th highest of 21 |
| Revenue growth (TTM) | +58.2% | +11.5% | 4th highest of 21 |
| Operating margin | 13.8% | 15.1% | 11th highest of 21 |
| Forward P/E | 56.6× | 16.4× | 2nd most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 10.4% | 7.2% | 7th most demanding of 15 |
| Growth delivered (Del g) | +45.5% | +9.3% | highest of 15 |
| Hurdle (Req g minus delivered) | -35.0 pp | -1.9 pp | least demanding of 15 |
| ROIC minus cost of capital | +62.5 pp | +1.7 pp | 2nd highest of 19 |
| EV / EBITDA | 52.2× | 22.6× | 2nd most expensive of 12 |
| Net debt / EBITDA | -4.2× | 0.2× | least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $7.57B | -14% | +8% | 6% | 14.8× | 2.9% | +6.6% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 37.4× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% | +8.1% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |